Spots Global Cancer Trial Database for rociletinib
Every month we try and update this database with for rociletinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC) | NCT02705339 | Carcinoma, Non-... Non-Small Cell ... Nonsmall Cell L... | Rociletinib Biopsy Blood draw | 18 Years - | Washington University School of Medicine | |
| Rociletinib (CO-1686) USA Expanded Access Program | NCT02547675 | Non-small Cell ... | Rociletinib | 18 Years - | Clovis Oncology, Inc. | |
| TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy | NCT02322281 | Non-small Cell ... | Rociletinib Pemetrexed or g... | 18 Years - | Clovis Oncology, Inc. | |
| TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy | NCT02322281 | Non-small Cell ... | Rociletinib Pemetrexed or g... | 18 Years - | Clovis Oncology, Inc. | |
| Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC) | NCT02705339 | Carcinoma, Non-... Non-Small Cell ... Nonsmall Cell L... | Rociletinib Biopsy Blood draw | 18 Years - | Washington University School of Medicine | |
| TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy | NCT02186301 | Non-Small Cell ... | Rociletinib Mon... Erlotinib Mono-... | 18 Years - | Clovis Oncology, Inc. | |
| Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients | NCT01526928 | Locally Advance... | Rociletinib Rociletinib Rociletinib Rociletinib Rociletinib Rociletinib | 18 Years - | Clovis Oncology, Inc. | |
| Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer | NCT02147990 | Non-small Cell ... | Rociletinib | 18 Years - | Clovis Oncology, Inc. | |
| A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC | NCT02630186 | Non-small Cell ... | Rociletinib MPDL3280A | 18 Years - | Clovis Oncology, Inc. | |
| TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy | NCT02322281 | Non-small Cell ... | Rociletinib Pemetrexed or g... | 18 Years - | Clovis Oncology, Inc. | |
| Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer | NCT02580708 | Non-small Cell ... | Rociletinib Trametinib | 18 Years - | Clovis Oncology, Inc. | |
| Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer | NCT02147990 | Non-small Cell ... | Rociletinib | 18 Years - | Clovis Oncology, Inc. | |
| A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC | NCT02630186 | Non-small Cell ... | Rociletinib MPDL3280A | 18 Years - | Clovis Oncology, Inc. | |
| TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy | NCT02186301 | Non-Small Cell ... | Rociletinib Mon... Erlotinib Mono-... | 18 Years - | Clovis Oncology, Inc. | |
| TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy | NCT02322281 | Non-small Cell ... | Rociletinib Pemetrexed or g... | 18 Years - | Clovis Oncology, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
